Amneal Mixed Q4 Earnings, Plans Expansion In High-Growth Areas Like Weight Loss Products, Biosimilars

 

• Amneal reported Q4 sales of $730.52M, up 18% Y/Y, beating estimates, while adjusted EPS of $0.12 missed the $0.15 consensus.
• 2025 guidance: Revenue of $3B-$3.1B, adjusted EPS of $0.65-$0.70, and adjusted EBITDA of $650M-$675M.
• https://www.benzinga.com/general/health-care/25/02/44040038/generic-drugmaker-amneal-clocks-mixed-q4-earnings-plans-expansion-in-high-growth-areas-like-weight-loss-products-biosimilars
•